DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
— - 1 Austin Walters - 1 Walters - 1 Henry Ford - 1 We're - 1 SpringTide - 1 Justin Hackworth Photgraphy SpringTide - 1 OpenLoop - 1
Top related locs:
Boston San Francisco Salt Lake City New York Danish Bengaluru
Top related orgs:
Sonic Healthcare - 2 Service - 1 SpringTide Ventures - 1 Tiger Global - 1 Business - 1 Health - 1 Ally Bank - 1 Troomi Wireless - 1

Search resuls for: "Sonic Healthcare"


2 mentions found


☆ Health VC firm SpringTide Ventures just closed its second $65 million fund. Here's what a startup needs to get its backing.
  + stars: | 2024-04-17 | by ( Rebecca Torrence | ) www.businessinsider.com   time to read: +5 min
Read previewAustin Walters started SpringTide Ventures in 2018 to disrupt healthcare by democratizing access to health innovations. The firm just closed its second $65 million fund to make more of those bets. A tough fundraising environmentAfter closing on its first $20 million fund, which the firm began investing out of in 2019, SpringTide originally set a $100 million target in 2021 for its second fund, Walters said. SpringTide picks a different focus area each time — most recently, home health, where the firm has invested in companies like family primary care startup Nest Health. By solving significant problems with advanced technologies, these companies have natural competitive advantages that allow them to drive outsize returns for the firm, Walters said.
Persons: —, Austin Walters, Walters, Henry Ford, We're, SpringTide, Justin Hackworth Photgraphy SpringTide, OpenLoop, outsize, SpringTidew hasn't, " Walters Organizations: Service, SpringTide Ventures, Tiger Global, Sonic Healthcare, Business, Health, Ally Bank, Troomi Wireless Locations: Boston, San Francisco, Salt Lake City, New York
☆ Australia's CSL tanks as Novo Nordisk's kidney trial success stokes competition concerns
  + stars: | 2023-10-12 | by ( Archishma Iyer | ) www.reuters.com   time to read: +1 min
Oct 12 (Reuters) - Shares of biotechnology firm CSL (CSL.AX) fell to a four-year low on Thursday, after rival Novo Nordisk's (NOVOb.CO) Ozempic drug showed early signs of success in delaying the progression of kidney disease in diabetes patients. Shares of CSL closed 5.7% lower at A$239.77, their lowest since Oct. 10, 2019, after falling 6.7% earlier in the session. The stock also marked its worst intraday session in four months and was the top loser on the benchmark. CSL's Vifor segment, which includes therapies for kidney diseases and iron deficiencies, faces concerns of competition in the segment after Ozempic's early trial success, analysts said. Reporting by Archishma Iyer in Bengaluru; Editing by Varun H KOur Standards: The Thomson Reuters Trust Principles.
Persons: Novo, Shane Ponraj, Morningstar, Tim Waterer, Archishma Iyer, Varun Organizations: CSL, Novo Nordisk's, CSL Vifor, Novo Nordisk, KCM Trade, Sonic Healthcare, Thomson Locations: Danish, Bengaluru
0 next >>
Total: 2